Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Tleyjeh, Imad M ^a,b,c   Bin Abdulhak, Aref A ^d   Riaz, Muhammad ^a   Alasmari, Faisal A ^a   Garbati, Musa A ^a   AlGhamdi, Mushabab ^a   Khan, Abdur Rahman ^e   Tannir, Mohamad Al ^a   Erwin, Patricia J ^c   Ibrahim, Talal ^f   AlLehibi, Abed ^a   Baddour, Larry M ^c   Sutton, Alex J ^g  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^f HAMAD MEDICAL CORPORATION   (Qatar)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; EPIDEMIOLOGICAL DATA; GRADE OF RECOMMENDATION ASSESSMENT DEVELOPMENT AND EVALUATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; PROTON PUMP INHIBITORS; RISK;

CLOSTRIDIUM DIFFICILE; SCOPUS;

EID: 84870946567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050836     Document Type: Review

References (53)

1. IMS Health (2005) Leading 20 therapeutic classes by U.S. sales, Available: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_73915261_77140565,00.html. Accessed 2006 June.
2. Yachimski PS, Farrell EA, Hunt DP, Reid AE, (2010) Proton Pump Inhibitors for Prophylaxis of Nosocomial Upper Gastrointestinal Tract BleedingEffect of Standardized Guidelines on Prescribing Practice. Arch Intern Med. 2010 170(9): 779-783.
3. Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL, (2007) Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 83: 66-68.
4. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, et al. (2010) Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 69(5): 543-552.
5. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ, (2005) Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 59: 31-34.
6. Niklasson A, Bajor A, Bergendal L, Simren M, Strid H, et al. (2003) Overuse of acid suppressive therapy in hospitalized patients with pulmonary diseases. Respir Med 97: 1143-1150.
7. Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, et al. (2005) Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci 50: 2307-2311.
8. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM, (2010) Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 66(12): 1265-1271.
9. US Food and Drug Administration (2009) Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). U.S. Department of Health and Human Services, 11/17/2009. http://www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Information for Patients and Providers/Drug Safety Information for Heath,care Professionals/ucm190787.htm. Accessed 9/23/2010.
10. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, et al. (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nation-wide propensity score-matched study. BMJ 342: d2690.
11. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS, (2011) Use of acid suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 9(3): 257-267.
12. Sierra F, Suarez M, Rey M, Vela MF, (2007) Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26: 545-553.
13. Johnstone J, Nerenberg K, Loeb M, (2010) Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 31(11): 1165-1177.
14. Dial MS. (2009) Proton pump inhibitor use and enteric infections. Am J Gastroenterol (suppl 2): S10-S16.
15. Leonard J, Marshall JK, Moayyedi P, (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047-2056.
16. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY, (2009) National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 37: 263-270.
17. Archibald LK, Banerjee SN, Jarvis WR, (2004) Secular trends in hospital-acquired Clostridium difficile disease in the United States. J Infect Dis 189: 1585-1589.
18. McDonald LC, Owings M, Jernigan JB, (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415.
19. Elixhauser A, Jhung M (2008) Clostridium difficile-associated disease in US hospitals, 1993-2005. HCUP statistical brief No. 50, April 2008. US Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs.sb50.pdf. Accessed February 16, 2009.
20. Redelings MD, Sorvillo F, Mascola L, (2007) Increase in Clostridium difficile-related mortality rates, United States, 1999e2004. Emerg Infect Dis 13(9): 1417-1419.
21. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, et al. (2012) Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J Gastroenterol 107(7): 1011-1019.
22. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, et al. (2012) Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10(3): 225-233.
23. Bavishi C, Dupont HL, (2011) Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34(11-12): 1269-1281.
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA 283: 2008-2012.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009 339: b2700.
26. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, et al. (2008) Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
27. Wells G, Shea B, O'Connell D, Peterson J, Welch Vet al. The Newcastle- Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa, Ontario: The Ottawa Health Research Institute. Available: http://www.ohri.ca/programs/clinicalepidemiology/nosgen.doc. Accessed on 2011 September 13.
28. Higgins JPT, Altman DG (2008) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008. Available: www.cochrane-handbook.org. Accessed 2010 December 15.
29. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177-188.
30. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2008) Contour-enhanced meta-analysis funnel plots help distinguishing publications bias from other causes of asymmetry. J Clin Epidemiol 61: 991-996.
31. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
32. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, et al. (2009) Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol 9: 2.
33. Schneeweiss S, (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15: 291-303.
34. Zhang J, Yu KF, (1998) What's a relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280: 1690-1691.
35. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D, (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171(1): 33-38.
36. Kutty PK, Woods CW, Sena AC, (2010) Risk Factors for and Estimated Incidence of Community-associated Clostridium difficile Infection, North Carolina, USA. Emerg Infect Dis 16(2): 197-204.
37. Jayatilaka S, Shakor R, Eddi R, Bakaj G, Baddoura WJ, et al. (2007) Clostridium difficile Infection in an Urban Medical Centre: Five-year Analysis of Infection Rates among Adults admissions and Association with the Use of Protein Pump Inhibitors. Ann Clin Lab Sci 37(3): 241-247.
38. Linney S, Fernandes T, Einarson T, Sengar A, Walker JH, et al. (2010) Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. Can J Hosp Pharm 63(1): 31-37.
39. http://www.cochrane-net.org/openlearning/html/mod14-2.htm.
40. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, Zadvornova Y, Dye A, et al. (2010) Clostridium difficile is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective. Am J Gastroenterol 105: 106-113.
41. Wilcox CM, Martin T, Phadnis M, Mohnen J, Worthington J, et al. (2008) Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. BMC Gastroenterol 8: 18.
42. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN, (2006) Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 43(10): 1272-1276.
43. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, et al. (2010) Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection. Arch Intern Med 170(9): 784-790.
44. Available: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.Accessed 2012 February 14.
45. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN, (2012) Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. Am J Gastroenterol 107(7): 1001-1010.
46. Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ, et al. (2009) Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ 339: b2981.
47. Jump RL, Pultz MJ, Donskey CJ, (2007) Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 51: 2883-2887.
48. Wilson KH, (1983) Efficacy of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18: 1017-1019.
49. Theisen J, Nehra D, Citron D, Johannson J, Hagen J, et al. (2000) Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 4: 50-54.
50. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, et al. (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 39: 54-59.
51. Nerandzic MM, Pultz MJ, Donskey CJ, (2009) Examination of Potential Mechanisms To Explain the Association between Proton Pump Inhibitors and Clostridium difficile Infection. Antimicrob Agents Chemother 53(10): 4133-4137.
52. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, et al. (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363: 1909-1917.
53. Boyce JM, Pittet D, (2002) Healthcare Infection Control Practices Advisory Committee; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Recomm Rep. 25 51(RR-16): 1-45.